PMID- 37715387
OWN - NLM
STAT- MEDLINE
DCOM- 20230918
LR  - 20230918
IS  - 1165-158X (Electronic)
IS  - 0145-5680 (Linking)
VI  - 69
IP  - 8
DP  - 2023 Aug 31
TI  - Denosumab Improves Glycaemic Parameters in Postmenopausal Osteoporosis Patients 
      with Combined Type 2 Diabetes Mellitus.
PG  - 185-191
LID - 10.14715/cmb/2023.69.8.28 [doi]
AB  - This study aimed to determine whether RANKL inhibitors in postmenopausal 
      osteoporosis patients with combined type 2 diabetes mellitus (T2DM) could improve 
      their glucose metabolism index. First of all, 84 patients affected with 
      postmenopausal osteoporosis with combined T2DM attending the Department of 
      Endocrinology at the Third Hospital of Hebei Medical University were selected and 
      randomized into two groups of 42 patients each. One group was given Denosumab 60 
      mg once every six months (denosumab group, D.G.), and the other group was given 2 
      mg ibandronate once every three months (ibandronate group, I.G.). Blood glucose 
      parameters were compared before and after treatment in both groups and serum 
      active GLP-1 levels and DPP-4 levels were also assessed. After treatment, there 
      was no significant difference in fasting glucose between the two groups, but 
      there was a significant decrease in fasting glucose in the Denosumab Group (D.G.) 
      compared to before treatment. There was a significant difference in 2-hour 
      postprandial glucose (2hPG) between the two groups after treatment, with the D.G. 
      being lower than the ibandronate group (I.G.). Glycosylated haemoglobin (HbA1c) 
      was lower in the D.G. than in the I.G. after treatment, but the difference 
      between them was insignificant. In the D.G., serum active GLP-1 levels increased 
      after treatment, and serum DPP-4 levels decreased. Serum GLP-1 and DPP-4 levels 
      in the I.G. did not change compared with those before treatment. In conclusion, 
      In the clinical management of postmenopausal osteoporosis patients with combined 
      T2DM, the choice of RANKL inhibitors as anti-osteoporosis therapy may benefit 
      their glycaemic parameters by elevating serum active GLP-1 levels and decreasing 
      serum DPP-4 levels.
FAU - Wang, Ke
AU  - Wang K
AD  - Department of Endocrinology, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei,050051, China. nimingren120@foxmail.com.
FAU - Gao, Liu
AU  - Gao L
AD  - Department of Endocrinology, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei,050051, China. 15232126366@163.com.
FAU - Liu, Chang
AU  - Liu C
AD  - Department of Endocrinology, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei,050051, China. 15613171905@163.com.
FAU - Bao, Xiaoxue
AU  - Bao X
AD  - Department of Endocrinology, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei,050051, China. 931533893@qq.com.
FAU - Tian, Yawei
AU  - Tian Y
AD  - Department of Endocrinology, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei,050051, China. 13451227421@163.com.
FAU - Li, Yukun
AU  - Li Y
AD  - Department of Endocrinology, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei,050051, China. liykun1962@163.com.
LA  - eng
PT  - Journal Article
DEP - 20230831
PL  - France
TA  - Cell Mol Biol (Noisy-le-grand)
JT  - Cellular and molecular biology (Noisy-le-Grand, France)
JID - 9216789
RN  - UMD7G2653W (Ibandronic Acid)
RN  - 4EQZ6YO2HI (Denosumab)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - IY9XDZ35W2 (Glucose)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Osteoporosis, Postmenopausal/complications/drug therapy
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Ibandronic Acid
MH  - Denosumab/therapeutic use
MH  - Glucagon-Like Peptide 1
MH  - Glucose
MH  - Transcription Factors
EDAT- 2023/09/16 10:43
MHDA- 2023/09/18 12:43
CRDT- 2023/09/16 01:30
PHST- 2023/06/01 00:00 [received]
PHST- 2023/09/18 12:43 [medline]
PHST- 2023/09/16 10:43 [pubmed]
PHST- 2023/09/16 01:30 [entrez]
AID - 10.14715/cmb/2023.69.8.28 [doi]
PST - epublish
SO  - Cell Mol Biol (Noisy-le-grand). 2023 Aug 31;69(8):185-191. doi: 
      10.14715/cmb/2023.69.8.28.